Keytruda, also known as pembrolizumab, received its first FDA approval in 2014 [1]. This initial approval was for the treatment of unresectable or metastatic melanoma in patients who had progressed on or after ipilimumab and, if BRAF V600E positive, a BRAF inhibitor [1][2].
What other cancers is Keytruda approved for?
Since its initial approval, Keytruda has received numerous subsequent FDA approvals for a wide range of cancer types and indications. These include, but are not limited to, advanced non-small cell lung cancer, classical Hodgkin lymphoma, urothelial carcinoma, and various types of head and neck squamous cell carcinoma [2]. Its approvals have expanded to cover earlier stages of certain cancers, as well as combinations with other therapies [2].
When does Keytruda's patent expire?
Patent expirations for Keytruda are complex and involve multiple patents covering different aspects of the drug, including its composition, manufacturing, and methods of use [3]. The earliest expected patent expiries are anticipated in the late 2020s, with some key patents potentially expiring around 2028 [3]. However, ongoing patent litigation and potential exclusivities may influence the actual market entry timelines for biosimilars [3].
How is Keytruda manufactured?
Keytruda is a humanized monoclonal antibody, produced using recombinant DNA technology in Chinese Hamster Ovary (CHO) cell culture [4]. This sophisticated biological manufacturing process is designed to ensure the production of a highly pure and potent therapeutic protein [4].
What are the main competitors to Keytruda?
Keytruda, as a programmed death receptor-1 (PD-1) inhibitor, faces competition from other checkpoint inhibitors. Major competitors include Opdivo (nivolumab) from Bristol Myers Squibb, which targets PD-1, and Yervoy (ipilimumab) from Bristol Myers Squibb, which targets cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) [5]. Other PD-1 inhibitors from different manufacturers are also in development or on the market, contributing to a competitive landscape in immuno-oncology [5].
What are the risks associated with Keytruda treatment?
Keytruda can cause immune-related side effects, where the immune system attacks healthy organs and tissues [6]. These can occur during treatment or even after stopping treatment and can affect any part of the body [6]. Common immune-related side effects include pneumonia, colitis, hepatitis, endocrinopathies (such as thyroid disorders, adrenal insufficiency, and diabetes), nephritis, and skin reactions [6]. Severe cases can be life-threatening [6].
Can biosimilars be developed for Keytruda?
Yes, biosimilars for Keytruda can be developed. However, the development and approval process for biosimilars is subject to regulatory pathways and intellectual property rights, including patent protections [3][7]. The availability of biosimilars depends on the expiry of relevant patents and successful navigation of regulatory approval for bioequivalence and interchangeability [7].
What is the clinical data supporting Keytruda's use?
Extensive clinical trial data supports Keytruda's efficacy and safety across numerous cancer types [2]. These trials have demonstrated significant improvements in overall survival, progression-free survival, and objective response rates compared to chemotherapy or placebo in various treatment settings [2]. The data continues to evolve as new trials are completed and Keytruda is studied in new combinations and indications [2].
How does Keytruda work?
Keytruda works by blocking the interaction between the PD-1 receptor on T cells and its ligands, PD-L1 and PD-L2 [4]. This blockade releases the "brakes" on the immune system, allowing T cells to more effectively recognize and attack cancer cells [4].
What is the pricing of Keytruda?
The pricing of Keytruda is substantial, reflecting its development costs and clinical value. Pricing structures can vary based on dosage, indication, and country. Information on the exact list price can be found through pharmaceutical pricing databases and manufacturer resources [8].
Sources:
[1] https://www.fda.gov/drugs/resources-information-approved-drugs/fda-drug-approvals-and-continuances
[2] https://www.merck.com/news/keytruda-pembrolizumab-is-a-first-in-class-pd-1-inhibitor-that-has-been-approved-by-the-u-s-food-and-drug-administration-fda-for-the-treatment-of-patients-with-advanced-unresectable-or-metastatic-melanoma-who-have-had-disease-progression-on-or-after-ipilimumab-and-if-braf-v600e-positive-a-braf-inhibitor/
[3] https://drugpatentwatch.com/
[4] https://www.merck.com/about/our-science/keytruda/
[5] https://www.cancer.gov/about-cancer/treatment/drugs/immunotherapy-drugs
[6] https://www.keytruda.com/hcp/about-keytruda/safety-information/
[7] https://www.fda.gov/vaccines-blood-biologics/biosimilars/about-biosimilars
[8] https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?IngredientName=PEMBROLIZUMAB